Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Oculis Reports Q3 2025 Financial Results and Provides Company Update
Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) andNon-arteritic Anterior Ischemic Optic Neuropathy (NAION) following positive FDA meeting OCS-01 DIAMOND Phase 3 trials in diabetic macular edema (DME) remain on track for topline results expected in Q2 2026 Licaminlimab PREDICT-1 registrational trial, thefirst genotype-based trial to drive precision medicine in dry eye disease (DED), expected to...
Nasdaq GlobeNewswire
10/11/2025
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
COPENHAGEN, Denmark, November 10, 2025– Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4,94% of the shares and voting rights in Bavarian Nordic A/S as of November 4, 2025.About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox...
Nasdaq GlobeNewswire
10/11/2025
Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields…
Developed through a collaborative research effort, two enhancers have now been tested at multiple scales in HEK293 cells using Ascend's EpyQ® two-plasmid AAV Production System and a commercially available 3-plasmid system, with no negative effects on quality parameters such as vg/cap ratio or mispackaged DNA being observed. Enhancer activity was further confirmed using customer plasmids. Developed through a collaborative research effort, two enhancers have now been tested at multiple scales…
PR Newswire
10/11/2025
Idorsia’s aprocitentan improved key prognostic indicators in patients with…
New analysis from landmark Phase 3 PRECISION trial published in theJournal of Hypertensionhighlights aprocitentan led to improvements in dipping pattern and BP loadFindings reinforce the role of aprocitentan’s novel endothelin pathway mechanism in addressing significant medical need in difficult-to-control hypertensionAllschwil, Switzerland – November 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in the...
Nasdaq GlobeNewswire
10/11/2025
NTG Nordic Transport Group publishes interim report for Q3 2025
Company announcement no. 10 – 25 10 November 2025 NTG Nordic Transport Group publishes interim report for Q3 2025The interim report for Q3 2025 is enclosed.In connection with publication of the results for Q3 2025, a conference call will be hosted on 11 November 2025 at 10:00 AM CET.The conference call will be held in English and can be followed live via NTG’s website ; investor.ntg.com. Additional information For additional information, please contact: Investor relations...
Nasdaq GlobeNewswire
10/11/2025
Patient Monitoring Devices Market to be Worth $118.21 Billion by 2033 at CAGR of…
Request a free sample copy of this report: Patient Monitoring Devices Market Request a free sample copy of this report:Patient Monitoring Devices Market Innovation is a key driver, accelerating with advancements in AI-enabled analytics, cellular connectivity, and device interoperability, pushing companies toward smart, patient-friendly solutions that offer continuous, reliable data and predictive insights for proactive care models. A notable example is Roche'sJuly 2024CE mark...
PR Newswire
10/11/2025
Genmab Provides Certain Information Disclosed in Connection with Proposed…
Media ReleaseCOPENHAGEN, Denmark; November 10, 2025Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market and other conditions, $1.5 billion of senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”).Genmab also launched the syndication of a new $2.0 billion senior...
Nasdaq GlobeNewswire
10/11/2025
Capnography Equipment Market worth $0.67 billion by 2030 with 4.6% CAGR |…
Browse in-depth TOC on "Capnography Equipment Market" Browse in-depth TOC on "Capnography Equipment Market" 421 - Tables 59 - Figures 320 - Pages By product,Capnography accessories and disposables lead the capnography equipment market, capturing the largest share due to their essential role in ensuring accurate and continuous CO2 monitoring in clinical settings. Items such as nasal and oral cannulas, sampling lines, airway adapters, and filters are crucial for both...
PR Newswire
10/11/2025
Novartis opens new radioligand therapy manufacturing facility in California as…
Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and HawaiiFirst to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and TexasBasel, November 10, 2025– Novartis, a leading...
Nasdaq GlobeNewswire
10/11/2025
Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver…
This post hoc analysis of the ESSENCE trial evaluated the first 800 randomized patients at 72 weeks. Histological and non-invasive testing (NIT)–related treatment responses were evaluated according to specific weight loss thresholds (≤2%, ≤5%, ≤7%, >7%).1 Steatohepatitis-related NITs improved in all groups receiving semaglutide 2.4 mg, with the greatest treatment effect observed for alanine aminotransaminase (ALT) in patients with weight loss of ≤7%. In this subgroup, patients receiving…
PR Newswire
10/11/2025
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7…
- Preclinical data reveal potential applications in hemolytic anemias and obesity-induced inflammatory anemia - - Preclinical data reveal potential applications in hemolytic anemias and obesity-induced inflammatory anemia - LEHI, Utah , Nov. 10, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced six poster presentations and one oral presentation at the 67 thAmerican Society of...
PR Newswire
10/11/2025
Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation…
The addition of this role represents an important step in CEO Kenneth Bilenberg's strategy to position Avid for continued expansion – and to be the easiest external partner to work with: reliable, predictable, and proactive at every stage. The addition of this role represents an important step in CEOKenneth Bilenberg'sstrategy to position Avid for continued expansion – and to be the easiest external partner to work with: reliable, predictable, and proactive at every stage. "Avid has...
PR Newswire
10/11/2025
Cellex Symposium 2025 Brings Together International Experts to Discuss the…
Driving Innovation and Investment in the Next Era of Immune Cell Therapies Driving Innovation and Investment in the Next Era of Immune Cell Therapies The opening session focused on innovation, funding, and the next generation of immune cell therapy platforms. Dr. Karl Nägler, Sofinnova Partners, provided an insightful overview of venture capital opportunities and challenges in CGT investments, whileKenneth Lockediscussed the use of cell-derived nanoparticles to overcome key barriers...
PR Newswire
10/11/2025
Brainomix Recognized in Global Health Tech Competition for Its Innovative…
"We're honored to be recognized by the American Heart Association for our Brainomix 360 Stroke technology," said Michalis Papadakis, Ph.D., Chief Executive Officer and Co-Founder of Brainomix. "This award affirms our commitment to transforming cardiovascular and stroke care through innovation and scientific rigor." "We're honored to be recognized by the American Heart Association for our Brainomix 360 Stroke technology," saidMichalis Papadakis, Ph.D., Chief…
PR Newswire
10/11/2025
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through…
/Cas9 license agreement. This agreement grants Dyadic access to ERS’ CRISPR/Cas9 patent portfolio, enhancing Dyadic’s ability to accelerate strain engineering and pathway optimization to enhance productivity, product quality, and innovation across its proprietary bioproduction platforms.“Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s proprietary...
Nasdaq GlobeNewswire
10/11/2025
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior…
Media ReleaseCOPENHAGEN, Denmark; November 10, 2025Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, subject to market and other conditions, $1.5 billion of senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”).Genmab also launched the syndication of a new $2...
Nasdaq GlobeNewswire
10/11/2025
Zenos Health Summit 2025 Concludes Transformative Three-Day Gathering of Global…
The gathering underscores Saudi Arabia's emergence as a global hub for health innovation and longevity science, attracting leading experts and practitioners from around the world. Attendee feedback was overwhelmingly positive, with 80% reporting the summit exceeded expectations and 90% expressing intent to return in 2026 The gathering underscoresSaudi Arabia'semergence as a global hub for health innovation and longevity science, attracting leading experts and practitioners from around the…
PR Newswire
10/11/2025
uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate…
~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 months and supportive trends across key clinical and biomarker endpoints ~~ Preliminary feedback from FDA at a recent pre-Biologics License Application (BLA) meeting for AMT-130 indicated a key shift from prior regulatory communications; uniQure plans to urgently interact with...
Nasdaq GlobeNewswire
10/11/2025
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial…
Atopic dermatitis is a chronic, recurrent, inflammatory skin disease characterized by symptoms such as dry skin, intense itching, and erythema, which significantly impact patients' quality of life. As a high medical need for the treatment of moderate to severe AD remains, there are opportunities to further optimise treatment options and technologies. Atopic dermatitis is a chronic, recurrent, inflammatory skin disease characterized by symptoms such as dry skin, intense itching, and erythema,...
PR Newswire
10/11/2025
A milestone moment for Interlinked - first major distribution agreement signed…
"This is a pivotal moment for Interlinked. Securing a guaranteed revenue of this size at such an early stage of commercialisation is a clear validation of both the demand and the impact of our solution. Now we accelerate," says Katarina Hedbeck, CEO and co-founder of Interlinked AB. " This is a pivotal moment for Interlinked. Securing a guaranteed revenue of this size at such an early stage of commercialisation is a clear validation of both the demand and the impact of our…
PR Newswire
10/11/2025
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market…
REYKJAVIK, ICELAND (November 10, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron’s and Bayer’s injunction...
Nasdaq GlobeNewswire
10/11/2025
Trillion-Dollar Digital Healthcare Transformations Shaped by AI, Quantum and…
From13-17 October 2025, the 45th edition of the world's largest tech and AI show united 6,800 exhibitors, 2,000 startups, and delegations from 180 nations, with digital health and biotech emerging as some of the most dynamic narratives of the week. From genome editing to neurotech and quantum medicine,GITEX GLOBALbecame the platform where the world's brightest minds explored how technology is fundamentally rewriting the science of life. AI's Healthcare Rise: From Genetic Code...
PR Newswire
10/11/2025
Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T…
To date, treatment with LEU011 has been generally well tolerated. In addition, disease control (based on RECIST criteria) has been observed in multiple patients treated with the lowest dose of LEU011. Dose-escalation in the AERIAL trial continues as planned, with additional data from the trial anticipated during the first half of 2026. To date, treatment withLEU011has been generally well tolerated. In addition, disease control (based on RECIST criteria) has been observed in multiple...
PR Newswire
10/11/2025
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
CAM2056 is a monthly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist formulated with Camurus' proprietary FluidCrystal® technology. CAM2056 is a monthly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist formulated with Camurus' proprietary FluidCrystal® technology. Topline results from the Phase1bstudy include: FluidCrystal® is a registered trademark of Camurus. Wegovy® is a registered trademark of Novo Nordisk. For more...
PR Newswire
10/11/2025
Altri Comunicati
